Bao Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 23-06-2024
- Paid Up Capital ₹ 1.25 M
as on 23-06-2024
- Company Age 17 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -77.82%
(FY 2022)
- Profit -41.14%
(FY 2022)
- Ebitda 46.52%
(FY 2022)
- Net Worth 0.63%
(FY 2022)
- Total Assets 18.45%
(FY 2022)
About Bao Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.25 M, as per Ministry of Corporate Affairs (MCA) records.
Ahmed Faraz, Mohd Haris, and Afshan Begum serve as directors at the Company.
- CIN/LLPIN
U24233DL2007PTC167941
- Company No.
167941
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Central Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Bao Pharma Private Limited offer?
Bao Pharma Private Limited offers a wide range of products and services, including Child and Baby Care Products, Baby Care Products, Pharmaceutical Tablets, Digestive System Drugs & Medicines, Anti Ulcer Drugs, Ayurvedic Immunity Booster, Chyawanprash, Honey & Sweeteners, Ayurvedic Herbal Syrups & Tonics, Ayurvedic Brain Tonic.
Who are the key members and board of directors at Bao Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ahmed Faraz  | Director | 10-Sep-2007 | Current |
| Mohd Haris | Director | 02-Jun-2023 | Current |
| Afshan Begum | Director | 10-Sep-2007 | Current |
Financial Performance of Bao Pharma.
Bao Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 77.82% decrease. The company also saw a substantial fall in profitability, with a 41.14% decrease in profit. The company's net worth moved up by a moderate rise of 0.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bao Pharma?
In 2018, Bao Pharma had a promoter holding of 28.00% and a public holding of 72.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bao Pharma?
Unlock and access historical data on people associated with Bao Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bao Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bao Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
